In a recently completed Phase II study evaluating the efficacy of the pan-Akt inhibitor MK2206 in recurrent platinum resistant ovarian cancer (“type”:”clinical-trial”,”attrs”:”text”:”NCT01283035″,”term_id”:”NCT01283035″NCT01283035), 4/5 patients reported…